Proteomics International (ASX: PIQ) secures a US patent protecting its PromarkerEndo endometriosis blood test through 2041, strengthening commercialisation and licensing opportunities.
Botanix (ASX: BOT) secures a major European patent milestone for Sofdra’s proprietary applicator technology, strengthening intellectual property protection and future licensing opportunities.
Imricor (ASX: IMR) expands its U.S. market after FDA pediatric clearance for the NorthStar Mapping System and Vision-MR Diagnostic Catheter, opening access to more than 250 children’s hospitals.
Echo IQ (ASX: EIQ) secures exclusive access to up to one million cardiovascular imaging studies through Advara HeartCare, strengthening its AI platform and long-term competitive advantage.
Echo IQ (ASX: EIQ) raises A$110 million to accelerate US expansion after FDA clearance, Pro Medicus partnership and Mayo Clinic collaboration, strengthening its AI cardiovascular platform.
Saluda Medical (ASX: SLD) has received FDA approval for its CAP24 Surgical Paddle Lead, expanding the Evoke System into the US surgical spinal cord stimulation market and unlocking access to approximately 30% more procedures.
Recce Pharmaceuticals (ASX:RCE) shares rise after signing a proposed 10-year Middle East licensing deal for its anti-infective diabetic foot infection treatment.
Alcidion secures a major NHS contract worth up to $49 million and acquires Telstra Health assets in a low-cost deal that expands recurring healthcare software revenue.
Nutritional Growth Solutions acquires Sprout Organic in an $8 million all-scrip deal, expanding into infant nutrition and lifting combined revenue to US$5.33 million.
Vitrafy (ASX: VFY) surged after US military-backed trial data showed its “No-Wash” blood preservation technology smashed global platelet recovery standards.
Pro Medicus and EOS strengthened their global positions with major healthcare imaging and defense infrastructure deals as enterprise software demand grows across international markets.
Pacific Edge rallies after a draft Medicare proposal restores coverage momentum for its Cxbladder cancer diagnostics in the United States.
Proteomics International (ASX: PIQ) secures a US patent protecting its PromarkerEndo endometriosis blood test through 2041, strengthening commercialisation and licensing opportunities.
Botanix (ASX: BOT) secures a major European patent milestone for Sofdra’s proprietary applicator technology, strengthening intellectual property protection and future licensing opportunities.
Imricor (ASX: IMR) expands its U.S. market after FDA pediatric clearance for the NorthStar Mapping System and Vision-MR Diagnostic Catheter, opening access to more than 250 children’s hospitals.
BCAL Diagnostics has unveiled BREASTEST Monitor, a blood test showing 91% sensitivity and 95% NPV for breast cancer recurrence detection, targeting millions of survivors globally.
Memphasys (ASX:MEM) secured an exclusive supply agreement with Monash IVF Group to deploy its Felix™ sperm selection technology across Australia, marking a major commercial milestone.
Echo IQ (ASX:EIQ) has launched a new Mayo Clinic research collaboration to evaluate its AI cardiac risk platform in cancer patients, expanding its reach into the growing cardio-oncology market.
DorsaVi (ASX: DVL) achieves breakthrough RRAM integration in biomedical sensors, boosting speed, efficiency, and system longevity. Chairman Gernot Abl outlines vision for next-gen AI healthcare devices.
Lumos Diagnostics Signs $487M Deal with PHASE Scientific – U.S. Launch of FebriDx® Nears FDA Milestone
Telix (ASX: TLX, NASDAQ: TLX) secures U.S. reimbursement code for its next-gen prostate cancer imaging agent Gozellix, boosting access and stock momentum. Shares up 6.91%.
ReNerve Ltd (ASX:RNV) secures Bahrain approval for its innovative NervAlign® Nerve Cuff™, marking a key milestone in global expansion. Shares up 9.5% as Middle East market opens up.
PainChek (ASX: PCK) surges 16% on Eldermark partnership news, targeting the US senior care market with its AI-powered pain assessment solution. FDA clearance awaited for full rollout.
ECS Botanics (ASX:ECS) shares jumped 22% as the company announced record FY25 cannabis output, lower costs, and a major B2C launch featuring premium Terphogz strains.
The Cook Government launches $3.5M medical research funding in partnership with THRF Group. Grants target preventative health and personalised medicine for priority populations across WA.
Immutep shares soar 10% after announcing 17.6-month median survival in PD-L1 CPS <1 head and neck cancer patients. FDA meeting requested for regulatory path.
Orthocell (ASX: OCC) gains 11.6% after securing Canadian approval for Remplir nerve repair device. Total addressable market climbs to US$1.8B amid global expansion push.
Nyrada Inc reports significant neuroprotective results for NYR-BI03 in a traumatic brain injury study. ASX-listed biotech now eyes human trial results in Q3 2025.
Cyclopharm shares rise after hitting US$1M in U.S. Technegas® sales. With 27 systems installed and federal contracts expanding, the company eyes global leadership.
Proteomics International (ASX: PIQ) has secured an Australian patent for its OxiDx oxidative stress diagnostic platform. Global rollout planned from mid-2025, targeting elite sports and horse racing markets..
%252520Strikes%252520Bonanza%25252047%252520%252520Antimony%252520at%252520Sunday%252520Creek%252520as%252520Critical%252520Minerals%252520Story%252520Gains%252520Momentum.webp&w=3840&q=75)